Adage Capital Partners GP L.L.C. Has $13.01 Million Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Adage Capital Partners GP L.L.C. lowered its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 4.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,500,000 shares of the biotechnology company's stock after selling 350,000 shares during the quarter. Adage Capital Partners GP L.L.C. owned about 5.59% of Heron Therapeutics worth $13,005,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of HRTX. Barclays PLC boosted its holdings in shares of Heron Therapeutics by 29.8% in the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock valued at $434,000 after acquiring an additional 50,109 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Heron Therapeutics by 456.5% during the 3rd quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company's stock valued at $204,000 after purchasing an additional 84,205 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Heron Therapeutics by 295.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock valued at $411,000 after purchasing an additional 154,487 shares in the last quarter. Congress Park Capital LLC increased its position in shares of Heron Therapeutics by 24.1% during the 4th quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock valued at $3,757,000 after purchasing an additional 477,417 shares during the period. Finally, Arkadios Wealth Advisors bought a new stake in shares of Heron Therapeutics in the 4th quarter worth $76,000. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Stock Down 1.7 %

Shares of NASDAQ HRTX traded down $0.04 during mid-day trading on Friday, hitting $2.31. 1,458,539 shares of the company traded hands, compared to its average volume of 2,299,876. Heron Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $3.93. The stock has a market capitalization of $351.88 million, a price-to-earnings ratio of -12.83 and a beta of 1.39. The business has a 50 day moving average of $2.17 and a two-hundred day moving average of $1.80.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. As a group, research analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HRTX. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a report on Friday, April 11th. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.